- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- May 2026
- 177 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- September 2026
- 140 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- April 2026
- 180 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- May 2026
- 350 Pages
Global
From €4663EUR$4,949USD£3,882GBP
- Report
- October 2026
- 160 Pages
Global
From €3128EUR$3,320USD£2,604GBP
€3910EUR$4,150USD£3,255GBP
- Report
- May 2026
- 132 Pages
Global
From €4569EUR$4,850USD£3,804GBP
- Report
- May 2026
- 300 Pages
Europe
From €3645EUR$3,869USD£3,035GBP
- Report
- November 2026
- 160 Pages
Africa, Middle East
From €3128EUR$3,320USD£2,604GBP
€3910EUR$4,150USD£3,255GBP
- Report
- October 2026
- 161 Pages
Global
From €6590EUR$6,995USD£5,487GBP
- Report
- August 2026
- 635 Pages
Global
From €1492EUR$1,639USD£1,200GBP
- Report
- December 2025
- 1135 Pages
Global
€1678EUR$1,844USD£1,350GBP
- Report
- October 2026
- 209 Pages
Global
From €4521EUR$4,799USD£3,764GBP
- Report
- July 2026
- 575 Pages
Global
From €4521EUR$4,799USD£3,764GBP
- Report
- June 2026
- 260 Pages
Global
From €4521EUR$4,799USD£3,764GBP
- Report
- June 2026
- 77 Pages
Global
From €4521EUR$4,799USD£3,764GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more